CN1326518C - 逍遥软胶囊及其制备工艺 - Google Patents
逍遥软胶囊及其制备工艺 Download PDFInfo
- Publication number
- CN1326518C CN1326518C CNB2004100335073A CN200410033507A CN1326518C CN 1326518 C CN1326518 C CN 1326518C CN B2004100335073 A CNB2004100335073 A CN B2004100335073A CN 200410033507 A CN200410033507 A CN 200410033507A CN 1326518 C CN1326518 C CN 1326518C
- Authority
- CN
- China
- Prior art keywords
- carefree
- grams
- soft capsule
- oil
- medicinal liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000008539 xiaoyao Substances 0.000 title abstract 4
- 238000005516 engineering process Methods 0.000 title description 4
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 239000000375 suspending agent Substances 0.000 claims abstract description 17
- 239000006187 pill Substances 0.000 claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 69
- 239000000843 powder Substances 0.000 claims description 28
- 239000000341 volatile oil Substances 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 18
- 239000000306 component Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 108010010803 Gelatin Proteins 0.000 claims description 15
- 239000008273 gelatin Substances 0.000 claims description 15
- 229920000159 gelatin Polymers 0.000 claims description 15
- 235000019322 gelatine Nutrition 0.000 claims description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 13
- 239000008158 vegetable oil Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 235000021050 feed intake Nutrition 0.000 claims description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000007766 cera flava Substances 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 230000005180 public health Effects 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 abstract description 16
- 239000002904 solvent Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 238000000465 moulding Methods 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 3
- 241001388844 Lorica Species 0.000 abstract 2
- 230000032798 delamination Effects 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 43
- 235000011187 glycerol Nutrition 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 201000010653 vesiculitis Diseases 0.000 description 8
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical group C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 210000001625 seminal vesicle Anatomy 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229960000452 diethylstilbestrol Drugs 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008925 spontaneous activity Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- -1 gives Chemical compound 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940012022 pentobarbital sodium 50 mg Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- GJLNWLVPAHNBQN-UHFFFAOYSA-N phenyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OC1=CC=CC=C1 GJLNWLVPAHNBQN-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
试验内容 | 均匀性 | 稳定性 | 成品率(%) | 装量差异 | 有效含量 |
AB | 不均匀均匀 | 不稳定稳定 | 2098 | 不符合规定符合规定 | 不符合制定的质量标准符合制定的质量标准 |
明胶∶甘油 | 10∶2 | 10∶3 | 10∶4 | 10∶5 | 10∶6 | 10∶6 |
囊壳外观物理性能崩解度(min) | 太硬易脆26±1.2 | 合适合适20±1.0 | 合适合适18±1.2 | 合适合适15±1.1 | 合适合适14±1.0 | 较软易吸潮10±1.2 |
组别 | 剂量(g/kg) | ALT(nmol·s-1/L) |
正常对照模型对照逍遥混悬液组逍遥微粉化混悬液组 | 等容量等容量9.09.0 | 656.87±57.182678.01+456.34△△1760.27±319.04**705.78±665.32**## |
组别 | 剂量(g/kg) | 终体质量(g) | 子宫湿质量(mg) | 体质量-子宫质量百分率(%) |
正常对照逍遥混悬液组逍遥微粉化混悬液组己烯雌酚 | 等容量9.09.00.001 | 13.1±2.2313.5±1.1912.8±2.1214.2±2.23 | 55±16.164±23.2△△84±17.2△△#▲▲250±85.0△△ | 4.35.16.823.6 |
组 别 | 剂量(g/kg) | 精囊质量(mg) | 体质量-精囊质量百分率(%) |
正常对照逍遥混悬液组逍遥微粉化混悬液组己烯雌酚 | 等容量9.09.00.002 | 215.2±30.35210.3±32.36▲172.5±22.31△▲168.4±31.76△ | 10.510.89.78.8 |
组别 | 剂量(g/kg) | 活动时间(s) |
正常对照逍遥混悬液组逍遥微粉化混悬液组 | 等容量9.09.0 | 542.87±57.18432±69.04△378.78±56.3△△ |
组 别 | 剂量(g/kg) | 入睡率(%) | 睡眠时间(min) |
正常对照逍遥混悬液组逍遥微粉化混悬液组 | 等容量9.09.0 | 253570 | 42.87±7.1852.23±10.04△86.78±9.33△△ |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100335073A CN1326518C (zh) | 2004-03-26 | 2004-03-26 | 逍遥软胶囊及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100335073A CN1326518C (zh) | 2004-03-26 | 2004-03-26 | 逍遥软胶囊及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1623599A CN1623599A (zh) | 2005-06-08 |
CN1326518C true CN1326518C (zh) | 2007-07-18 |
Family
ID=34763417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100335073A Expired - Lifetime CN1326518C (zh) | 2004-03-26 | 2004-03-26 | 逍遥软胶囊及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1326518C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102166341B (zh) * | 2011-03-30 | 2012-07-18 | 山西大学 | 一种逍遥散抗抑郁症提取物的制备方法 |
CN105853986A (zh) * | 2016-06-06 | 2016-08-17 | 李晓维 | 一种治疗乳腺增生的中药组合 |
CN111012891A (zh) * | 2019-12-26 | 2020-04-17 | 深圳市中医院 | 一种延缓动脉粥样硬化的中药组方及其制备方法 |
CN114699499A (zh) * | 2022-04-13 | 2022-07-05 | 浙江三溪堂中药有限公司 | 一种护肝和脾丸的制作方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1064258C (zh) * | 1998-03-17 | 2001-04-11 | 昆明制药股份有限公司 | 三七提取物软胶囊及其制备工艺 |
CN1429544A (zh) * | 2003-01-13 | 2003-07-16 | 内蒙古吉兰泰盐化集团呼和浩特制药厂 | 天然胡萝卜素软胶囊及其生产方法 |
CN1436568A (zh) * | 2003-03-05 | 2003-08-20 | 南京中山制药厂 | 一种治疗男性不育症的药物的制备方法 |
CN1451417A (zh) * | 2002-04-18 | 2003-10-29 | 北京天泰源医药技术开发有限公司 | 逍遥丸新剂型的制备工艺 |
-
2004
- 2004-03-26 CN CNB2004100335073A patent/CN1326518C/zh not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1064258C (zh) * | 1998-03-17 | 2001-04-11 | 昆明制药股份有限公司 | 三七提取物软胶囊及其制备工艺 |
CN1451417A (zh) * | 2002-04-18 | 2003-10-29 | 北京天泰源医药技术开发有限公司 | 逍遥丸新剂型的制备工艺 |
CN1429544A (zh) * | 2003-01-13 | 2003-07-16 | 内蒙古吉兰泰盐化集团呼和浩特制药厂 | 天然胡萝卜素软胶囊及其生产方法 |
CN1436568A (zh) * | 2003-03-05 | 2003-08-20 | 南京中山制药厂 | 一种治疗男性不育症的药物的制备方法 |
Non-Patent Citations (1)
Title |
---|
中华人民共和国卫生部药品标准中药成方制剂第十一册 中华人民共和国卫生部药典委员会编,164 1996 * |
Also Published As
Publication number | Publication date |
---|---|
CN1623599A (zh) | 2005-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100594928C (zh) | 姜黄提取物及其制备方法、药物组合物和用途 | |
CN102631377A (zh) | 冬虫夏草冻干纳米粉片及其制备方法 | |
CN100335088C (zh) | 治疗骨坏死病的中药制剂及其制备方法 | |
CN102188513A (zh) | 对化学性肝损伤具有辅助保护功能的药物组合物 | |
CN113995788B (zh) | 一种保肝、护肝的组合物及其制备工艺 | |
CN102727619A (zh) | 一种治疗脂肪肝的药物组合物及其制剂 | |
CN102240385B (zh) | 用于治疗妇女产后疾病的中药滴丸及其制备方法 | |
CN100469377C (zh) | 一种治疗前列腺炎的软胶囊 | |
CN1326518C (zh) | 逍遥软胶囊及其制备工艺 | |
CN101700275A (zh) | 一种含广枣的药物制剂及其制备方法与应用 | |
CN103610834B (zh) | 中药组合物及其制备方法和应用 | |
CN100518809C (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN1320881C (zh) | 一种治疗急慢性肝炎的滴丸 | |
CN101744931A (zh) | 祛痤疮的中药组合物、其制剂、制备方法及用途 | |
CN102552719A (zh) | 一种羚羊感冒胶囊制备过程中挥发油的添加方法 | |
CN101623477A (zh) | 一种降血脂中药组合物新工艺、新剂型的制备方法 | |
CN104173922A (zh) | 一种治疗瘿病的中药 | |
CN100496467C (zh) | 一种含有丹栀提取物的软胶囊及其制备方法 | |
CN103611074A (zh) | 采用部分药粉混匀后直接装入胶囊的乳康软胶囊制备工艺 | |
CN103520235A (zh) | 一种具有降脂功能的植物组合物及其制备方法与应用 | |
CN1872327B (zh) | 一种治疗腹泻的药物组合物 | |
CN1546088A (zh) | 一种治疗妇女痛经的中药制剂 | |
CN104338017B (zh) | 具有改善睡眠作用的药物组合物及制法和应用 | |
CN103142888B (zh) | 一种小儿七星茶的软胶囊制剂 | |
CN103372040B (zh) | 一种调节血脂的红曲川芎药物组合及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ENBIPU PHARMACY CO., LTD., SHIYAO GROUP. Effective date: 20130319 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050051 SHIJIAZHUANG, HEBEI PROVINCE TO: 050035 SHIJIAZHUANG, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130319 Address after: 050035 No. 226 the Yellow River Avenue, Shijiazhuang hi tech Development Zone, Hebei Patentee after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. Patentee after: SHIJIAZHUAN PHARMA GROUP NBP PHARMACEUTICAL Co.,Ltd. Address before: 050051 No. 276 West Zhongshan Road, Hebei, Shijiazhuang Patentee before: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070718 |
|
CX01 | Expiry of patent term |